CLSD: clearsidebio.com Price to Earnings Adjusted for Growth Rate

Corporate company logo of Clearside Corp (CLSD)

Clearside Biomedical (CLSD) relies on a staff of specialized scientists and clinical research experts. Microinjection systems serve as the key driver, as their implementation in clinics creates long-term demand for consumables. The adjusted PEG ratio confirms this potential, while the 0.00 metric reflects current dynamics. The business's stability is guaranteed by a unique method of suprachoroidal drug delivery.

CLSD Clearside Biomedical PEG Multiple (07/04/2022 - 12/13/2025)

Analytical breakdowns for Clearside Biomedical (CLSD)

- share price and consensus valuation forecast:
Price Performance Chart Clearside Biomedical Inc|CLSD - Analyst Consensus Forecast
- market capitalization information:
Market Value Clearside|CLSD - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Net Asset Value per Share Clearside Biomedical|CLSD - Book Capitalization|Market-to-Book Ratio clearsidebio.com|CLSD - Aggregate Company Assets
- business debt structure and liquidity details:
Total Debt to Capital Coefficient Clearside Biomedical|CLSD - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio clearsidebio.com|CLSD - Company Debts|Debt to Book Capitalization Ratio Clearside|CLSD - Company Long-Term Debts|Short-Term Debt Clearside Biomedical|Quick Ratio clearsidebio.com
- earnings and multiples data:
CLSD - Company Net Income|Expected Net Income Clearside Biomedical|CLSD - Price to Earnings Ratio|Market Cap to Projected Earnings Clearside Corp|CLSD - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Clearside|CLSD - Operating profit EBITDA|Earnings per share for the last 12 months Clearside Biomedical|CLSD - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months clearsidebio.com|CLSD - Net earnings per share growth this year|Expected earnings per share trend next year Clearside Biomedical
Fundamental company analysis:Clearside Biomedical Inc CLSD
Core merchandise of Clearside Biomedical, Inc.

Delegating ophthalmological research to a network of independent contractors minimizes operational risks for Clearside Biomedical (CLSD). The growth-weighted P/E trend reflects the market value of such strategic decisions. This metric compares the current earnings multiple with the annual growth rate of those earnings. A value below one signals that the asset is undervalued relative to its expansion. Investors should seek a balance between the discount and potential hidden business issues.

Competing companies

ALC (Alcon Inc) - Growth-Adjusted Payback Ratio|PEG Multiple BLCO (Bausch + Lomb Corp)|Glaukos Medical (GKOS) - Price to Earnings Adjusted for Growth Rate|APLS: Price/Earnings to Growth Multiple|Price to Earnings Adjusted for Growth Rate Belite Bio Inc|OCUL: PEG Multiple|Price to Earnings Adjusted for Growth Rate Harrow Inc (HROW)|Price/Earnings to Growth Ratio Viridian Pharma|LENZ Corp (LENZ) - Growth-Adjusted Market Cap to Net Income|PEG Multiple OCS|Price/Earnings to Growth Multiple eyepointpharma.com EYPT|Price/Earnings to Growth Ratio Kodiak Sciences KOD|Aldeyra Therapeutics Inc. - Price/Earnings to Growth Ratio|Kala Pharmaceuticals - PEG Multiple|Price to Earnings Adjusted for Growth Rate Opus Genetics Inc|OKYO: PEG Multiple|Adverum Biotechnologies, Inc. (ADVM) - PEG Multiple|Price/Earnings to Growth Ratio Outlook Therapeutics, Inc.|NBY: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Kiora Pharmaceuticals (KPRX)|Growth-Adjusted Market Cap to Net Income alimerasciences.com|PEG Multiple EYEN (Eyenovia)|Growth-Adjusted Market Cap to Net Income guardionhealth.com (GHSI)|Ocuphire Pharma - PEG Multiple|OPT (Opthea Ltd) - Growth-Adjusted P/E Ratio